N/A
N=102
Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection
Helicobacter Pylori Infection
Bottom Line
View on ClinicalTrials.gov: NCT02978157 ↗Enrolled (actual)
102
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcome: Primary: Number of Participants in Which H. Pylori Was Eradicated — 36; 49 participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- esomeprazole+amox+levo (Drug); esomeprazole+bismuth+tetra+levo (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Kaohsiung Veterans General Hospital.
- Primary completion
- Sep 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants in Which H. Pylori Was Eradicated |
36; 49 | <0.001 sig |
Summary
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
Eligibility Criteria
Inclusion Criteria
- positive results of both rapid urease test and histology,
- a positive result of urea breath test,
- or a positive result of culture.
Exclusion Criteria
- ingestion of antibiotics, bismuth, or proton pump inhibitor（PPI）within the prior 4 weeks,
- patients with allergic history to the medications used,
- patients with previous gastric surgery,
- the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia),
- pregnant women
Data sourced from ClinicalTrials.gov (NCT02978157). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.